|Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013|
Late Breaking Clinical Trial Features the First U.S. Data of Novel Self-Expanding Transcatheter Valve at Premier Interventional Cardiology Meeting
Other Late-Breakers Feature New Clinical Data on Endeavor and Resolute Drug-Eluting Stents; Three Year Results of Symplicity HTN-2 Study to be Presented
MINNEAPOLIS -- Oct. 17, 2013 -- Medtronic, Inc. (NYSE: MDT) today announced its schedule of notable sessions that will be presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium in San Francisco, including the highly-anticipated clinical outcomes from the Extreme Risk Study of the CoreValve U.S. Pivotal Trial.
The CoreValve Pivotal Trial presentation will kick-off the annual medical meeting's late-breaking clinical trials sessions this year, on the morning of Tuesday, Oct. 29.
"Unveiling the CoreValve U.S. Pivotal Trial data for the first time is a significant milestone as we work toward bringing more therapy options to patients in the U.S.," said John Liddicoat, M.D., senior vice president, Medtronic, and president of the Medtronic Structural Heart Business at Medtronic. "This study will provide vital information for physicians and their U.S. patients, many of whom have had no good option for treating their aortic stenosis."
Thursday's late-breaking clinical trials session includes two presentations involving Medtronic drug-eluting stents:
At an oral presentation at TCT, the three-year follow-up results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, will be presented.
The following presentations related to Medtronic therapies appear in chronological order in U.S. Pacific Daylight Time:
Tuesday 29 October
9:00 a.m. - 9:30 a.m. / TCT Press Conference for journalists with press credentials presented by the Cardiovascular Research Foundation (CRF)
10:35 a.m. - 11:45 a.m. / Plenary Session IV. Late Breaking Clinical Trials I
1:00 p.m. - 3:15 p.m. / Oral Abstract: Renal Denervation and Endovascular Intervention
4:00 p.m. - 5:00 p.m. / Medtronic Analyst and Investor Briefing
Thursday 31 October
9:30 a.m. - 10:40 a.m. / Plenary Session XVI. Late Breaking Clinical Trials III
The CoreValve System and the Symplicity Catheter System are not currently approved for commercial use in the United States and are undergoing clinical trials in the U.S. The Resolute Integrity DES obtained FDA approval in 2012 and, along with the Endeavor DES, is commercially available in the United States.
TCT Analyst and Investor Briefing
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- end -